Can we count your visit with Google Analytics? No ads, no profiles. Details
BSX
USHealth Care · Health Care Equipment
Each weekday: the watchlist of pullbacks inside uptrends, every new ticker teardown, and the bubble shifts that move names like this one. Free. Education, not advice.
Free when you join: the $HOOD Teardown Dossier (Robinhood Markets), the full desk file we sell in the shop. One per new reader.
No spam. One email per day max, unsubscribe in one click. Pro ($49/mo) includes every dossier and report in the shop.
Structural: medical-device compounder levered to two procedural growth engines - Watchman LAA closure (AFib stroke prevention) and FARAPULSE pulsed field ablation (AFib first-line). PFA is the fastest device launch in EP history; FARAPULSE captured majority US share within 12 months of approval and is cannibalising RF/cryo from $JNJ and $MDT.
Watchman compounds mid-teens on AFib prevalence + guideline tailwind. Endoscopy + urology (Rezum, SpaceOAR) provide non-cardio diversification.
PFA TAM expanding from paroxysmal to persistent AFib (FDA expansion pending); Watchman penetration <15% of eligible AFib population; pipeline (Watchman FLX Pro, AVANT GUARD trial) extends franchise; gross margin mix-up as PFA scales; M&A optionality (Axonics-style tuck-ins).
$JNJ Varipulse + $MDT PulseSelect closing the PFA gap with bigger sales forces; Watchman growth decelerates as easy AFib pool depletes; capital-intensive consumable mix; hospital capex pressure if rate cycle re-tightens; valuation premium (~30x fwd EPS) leaves no margin for execution slip.
It reads our $BSX data (thesis, key levels, peers, a year of prices) and any chart screenshot you paste, then explains the setup in plain English. Free with an email login, 5 questions a day. Education only: it never tells you to buy or sell, and it can be wrong, so check the numbers.
High-signal only
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.